NSC 1008 is a selective Ras converting enzyme 1 (Rce1) inhibitor that reduces Rce1 in vitro activity with a human IC50 of 8.9 μM. NSC 1008 demonstrates selectivity for Rce1 by not inhibiting human Ste24 or huamn FTase. NSC 1008 exhibits low cell toxicity, and induces mislocalization of EGFP-Ras from the plasma membrane in cancer cells. NSC 1008 can be used for the research of cancer.

NS8593 is an SK channel (small conductance Ca2+-activated K+ channels) inhibitor. NS8593 reversibly inhibited recombinant SK3-mediated currents (human SK3 and rat SK3). NS8593 inhibits all the SK1-3 subtypes Ca2+-dependently (Kd = 0.42, 0.60, and 0.73 μM, respectively, at 0.5 μM Ca2+). NS8593 does not affect the Ca2+-activated K channels of intermediate and large conductance (hlk and hBK channels, respectively). NS8593 can also inhibit TRPM7 (melastatin-related TRP cation channel 7) (IC50 = 1.6 mM). NS8593 can be used for the study of central nervous system (CNS) related diseases.

NS-181 is a MetAP2 inhibitor and antiamebic agent with oral effectiveness.NS-181 functionally inhibits methionine aminopeptidase 2, a protein critical for Entamoeba histolytica proliferation. NS-181 exerts antiamebic activity against Entamoeba histolytica, leading to resolution of amebic liver abscess. NS-181 can be used for the research of amebiasis.

NPSR1 modulator-1 is a NPSR1 modulator.

N-Phosphotaurocyamine (Taurocyamine phosphate) is a phosphagen in Arenicola, the stores of phosphotaurocyamine are an energy source which can be used for rapid regeneration of ATP.

NPFFR2 modulator-1 (compound 11) is a NPFFR2 modulator.

NPD15261 (MI102) is a highly selective MYCN inhibitor. NPD15261 reduces the mRNA and protein levels of MYCN in liver cancer cells, inhibits cell proliferation and colony formation, and induces Apoptosis simultaneously. NPD15261 can be used in liver cancer research.

NPC 573 is a Bradykinin analog. NPC 573 inhibits contraction of the uterus.

North-methanocarbathymidine (N-MCT) is a potent antiviral agent. North-methanocarbathymidine inhibits DNA synthesis. North-methanocarbathymidine demonstrates potent antiviral activity against HSV-1, HSV-2 and KSHV. North-methanocarbathymidine exhibits anticancer activity against colon adenocarcinoma expressing HSV-tk.

Norhyodeoxycholic acid (NHDCA) is a synthetic bile acid and a derivative of hyodeoxycholic acid (HDCA).

Norfloxacin succinil is a quinolone antibacterial agent. Norfloxacin succinil can be used in the research of infectious diseases such as urinary tract infections.

nNOS-IN-2 trihydrochloride is a blood-brain barrier-permeable nitric oxide synthase (nNOS) inhibitor. nNOS-IN-2 trihydrochloride exhibits Ki values of 1.7 nM and 2.3 nM against human and rat nNOS, respectively, and shows high selectivity for human eNOS and iNOS. nNOS-IN-2 trihydrochloride also effectively reduces PD-L1 expression in human melanoma cells under both basal conditions and IFN-γ exposure. nNOS-IN-2 trihydrochloride can be used for the study of melanoma and related signaling pathways.

NN-01-195 is a HSP90 inhibitor-drug conjugate. NN-01-195 binds tightly to and inhibits AURKA and HSP90, with an IC50 of 3.1 nM against AURKA and an IC50 of 8.7 nM against HSP90α. NN-01-195 induces mitotic arrest and spindle abnormality in tumor cells, and triggers cell apoptosis. NN-01-195 can be used in the research of solid tumors.

N-Methyl-4-(8-phenoxyoctoxy) aniline (Compound 3568) is an anti-schistosomal agent. N-Methyl-4-(8-phenoxyoctoxy) aniline exhibits definite anti-Schistosoma mansoni activity in mouse models, but has high acute toxicity. N-Methyl-4-(8-phenoxyoctoxy) aniline can be used in studies related to schistosomiasis.

NMDAR blocker 1 is an NMDA receptor channel blocker with an IC50 of 5.0 μM. NMDAR blocker 1 exhibits fast on-off blockade kinetics and strong voltage dependence, and does not compete with glutamate or glycine. NMDAR blocker 1 prevents glutamate/NMDA-induced intracellular Ca2+ overload, modulates the glutamate-nitric oxide-cGMP pathway. NMDAR blocker 1 prevents in vitro excitotoxic neurodegeneration of cultured cerebellar and hippocampal neurons. NMDAR blocker 1 attenuates excitotoxic insult in an mouse model of hyperammonemia-induced excitotoxicity. NMDAR blocker 1 can be used for the research of neurodegenerative diseases.

NLX-219 is a selective agonist of the 5-HT1A with a pKi of 10.21. NLX-219 activates ERK1/2 phosphorylation, inhibits adenylyl cyclase activity, promotes β-arrestin recruitment. NLX-219 can be used for the research of neurological disease.

NLRP3-IN-89 is a NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. NLRP3-IN-89 inhibits the NLRP3 inflammasome pathway, reduces IL-1β secretion, and exhibits minimal interference with the NF-κB pathway. NLRP3-IN-89 can be used for the research of Parkinson's disease, frontotemporal dementia, multiple system atrophy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, or brain injury.

NLRP3-IN-87 is a selective and orally active NLRP3 inhibitor with a Kd of 0.23 μM. NLRP3-IN-87 binds directly to the NLRP3 NACHT domain, disrupts NLRP3-NEK7 and NLRP3-ASC interactions, inhibits ASC oligomerization, and blocks inflammasome assembly. NLRP3-IN-87 suppresses caspase-1 activation and IL-1β secretion. NLRP3-IN-87 exhibits anti-inflammatory and analgesic activity, reducing joint swelling, inflammation, and pain in an MSU-induced acute gout mouse model. NLRP3-IN-87 can be used for the research of gout.

NLRP3-IN-86 (Compound 8a), a derivative of Songorine, is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-86 can reduce LPS- and Nigericin-stimulated lactate dehydrogenase (LDH) release (IC50 = 2.69 μM in THP-1 cells and 1.75 μ M in J774A.1 cells). NLRP3-IN-86 can inhibit gasdermin D (GSDMD) cleavage and IL-1β secretion. NLRP3-IN-86 can inhibit cell pyroptosis. NLRP3-IN-86 can be used for research of inflammation.

NLRP3 modulator 7 (Compound 17B) is a NLRP3 inflammasome regulator. NLRP3 modulator 7 has inhibitory activity against IL-1b, and its IC50 is less than 500 nM.

Nivimedone (BRL 10833 free base) is an orally active antiallergic agent. Nivimedone inhibits IgE-mediated passive cutaneous anaphylaxis in rats. Nivimedone suppresses antigen-induced histamine release from lung tissues passively sensitized with atopic serum. Nivimedone can be used in research related to bronchial asthma.

Nitramisole is a nitrobenzene-heterocycle conjugate and microfilaricide. Nitramisole kills microfilariae of Brugia malayi, Dipetalonema viteae and Litomosoides carinii. Nitramisole can be used for the research of filariasis (Brugia malayi, Dipetalonema viteae, Litomosoides carinii infections).

Niravoline (RU51599) is an arginine vasopressin (AVP) release inhibitor and a selective kappa opioid receptor agonist. Niravoline has a pure water diuresis effect without associated electrolyte excretion. Niravoline can reduce brain oedema following transient forebrain ischaemia in rats.

NIP 502 is a pyridazinone derivative with orally active anti-inflammation and anti-immunology effects. NIP 502 can be used for the research of asthma.

NHWL071065 is a IKZF1/IKZF3 degrader. NHWL071065 selectively degrades IKZF1 and IKZF3 in lymphoma cells via the ubiquitin-proteasome pathway. NHWL071065 inhibits the proliferation of lymphoma cells. NHWL071065 downregulates proteins involved in cytoskeleton assembly, cell adhesion and immune regulation in cells, while upregulating proteins related to the type I IFN signaling pathway. NHWL071065 can be used in the research of lymphoma.

NHS-Phosphine is an amine-reactive compound that can be used to derivatize primary amines of proteins or amine-coated polymer surfaces for ligation to azide-tagged molecules.

NGI‑189 is a selective OST‑A inhibitor. NGI‑189 inhibits the STT3A catalytic subunit of the OST complex and reduces N‑glycosylation of target glycoproteins. NGI‑189 blocks oncogenic and bypass signaling, reduces phosphorylation of EGFR, AKT, p70S6K and S6RP, and induces cell cycle arrest and apoptosis. NGI‑189 markedly suppresses tumor growth and induces tumor regression in non‑small cell lung cancer (NSCLC) xenograft models. NGI‑189 can be used for the research of EGFR‑mutant non‑small cell lung cancer.

NFYi5 is a nuclear transcription factor-Y (NF-Y) inhibitor. NFYi5 disrupts the binding of NF-Y to DNA, accelerates the ubiquitin-independent degradation of the NF-YA subunit, and reduces the transcriptional activity of NF-Y. As an antimitotic agent, NFYi5 decreases the mRNA levels of NF-Y target genes without affecting the expression of housekeeping genes, and inhibits cell proliferation. NFYi5 can be used in the research of tissue fibrosis.

NFE2L2 activator 3 (Compound 3) is a NFE2L2/NRF2 activator. NFE2L2 activator 3 specifically activates the NAD(P)H:quinone oxidoreductase (NQO1) enzyme, with its EC50 < 1 nM. NFE2L2 activator 3 can be used for research on respiratory system diseases such as chronic obstructive pulmonary disease.

NFE2L1 activator-1 (Compound 5b) is a potent nuclear factor erythroid 2-related factor 1 (NFE2L1) activator (EC50 = 2.4 µM). NFE2L1 activator-1 effectively resists ferroptosis (Ferroptosis). NFE2L1 activator-1 can specifically activate the NFE2L1 signaling pathway to upregulate GPX4, PSMB7, PSMC4. NFE2L1 activator-1 can be used in cancer research.